Your browser doesn't support javascript.
loading
Progress of apatinib in the treatment of ovarian cancer / 中国综合临床
Clinical Medicine of China ; (12): 563-567, 2022.
Article Dans Chinois | WPRIM | ID: wpr-956419
ABSTRACT
Ovarian cancer (OC) has the highest mortality rate among gynecological malignancies. Its treatment has always been a difficult problem and the focus of exploration in the medical field. In recent years, anti-angiogenic drugs have shown good anticancer effects in the treatment of ovarian cancer. As a new generation of antiangiogenic drugs, apatinib has been proved to have a good therapeutic effect in the treatment of ovarian cancer with less adverse reactions. Therefore, we review the research progress of apatinib in ovarian cancer.

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: Clinical Medicine of China Année: 2022 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: Clinical Medicine of China Année: 2022 Type: Article